Ultragenyx Pharma (RARE) Misses Q1 EPS by 28c

Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.03), $0.28 worse than the analyst estimate of ($1.75). Revenue for the quarter came in at $108.8 million versus the consensus estimate of $116.25 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Worried the AI trade has gone too far? Evercore likes these 4 stocks
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating